FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2999597478> ?p ?o ?g. }

• W2999597478 endingPage "259" @default.
• W2999597478 startingPage "259" @default.
• W2999597478 abstract "Despite the benefits of pioglitazone in the treatment of non-alcoholic fatty liver disease (NAFLD), many treated patients continue to experience disease progression. We aimed to investigate the additive effect of ipragliflozin on NAFLD in patients with type 2 diabetes treated with metformin and pioglitazone. In this 24-week randomized controlled trial, 44 patients with type 2 diabetes and comorbid NAFLD were either randomized to receive 50 mg/day of ipragliflozin as an add-on treatment (n = 29) or maintained on metformin and pioglitazone (n = 15). The fatty burden was assessed using the fatty liver index, NAFLD liver fat score, and controlled attenuation parameter (CAP). Changes in fat and muscle depots were measured by dual-energy x-ray absorptiometry and abdominal computed tomography scans. The enrolled patients were relatively controlled (mean baseline glycated hemoglobin of 6.6% ± 0.6%) and centrally obese (mean waist circumference of 101.6 ± 10.9 cm). At week 24, patients in the ipragliflozin add-on group exhibited reduced hepatic fat content (fatty liver index: -9.8 ± 1.9, p = 0.002; NAFLD liver fat score: -0.5 ± 0.2, p = 0.049; CAP: -8.2 ± 7.8 dB/m2, p = 0.133). Ipragliflozin add-on therapy also reduced whole-body visceral fat and the ratio of visceral to subcutaneous fat (change in whole-body visceral fat: -69.6 ± 21.5 g; change in abdominal visceral fat: -26.2 ± 3.7 cm2; abdominal visceral to subcutaneous fat ratio: -0.15 ± 0.04; all p < 0.05). In conclusion, ipragliflozin treatment significantly ameliorates liver steatosis and reduces excessive fat in euglycemic patients with type 2 diabetes and NAFLD taking metformin and pioglitazone." @default.
• W2999597478 created "2020-01-23" @default.
• W2999597478 creator A5007204226 @default.
• W2999597478 creator A5013273392 @default.
• W2999597478 creator A5030439670 @default.
• W2999597478 creator A5071307339 @default.
• W2999597478 creator A5087216936 @default.
• W2999597478 date "2020-01-18" @default.
• W2999597478 modified "2023-10-17" @default.
• W2999597478 title "Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial" @default.
• W2999597478 cites W1689732359 @default.
• W2999597478 cites W1714643869 @default.
• W2999597478 cites W1982905493 @default.
• W2999597478 cites W1990055069 @default.
• W2999597478 cites W2024044572 @default.
• W2999597478 cites W2044921326 @default.
• W2999597478 cites W2051243940 @default.
• W2999597478 cites W2062812115 @default.
• W2999597478 cites W2072627042 @default.
• W2999597478 cites W2077636750 @default.
• W2999597478 cites W2103156933 @default.
• W2999597478 cites W2105196519 @default.
• W2999597478 cites W2108550834 @default.
• W2999597478 cites W2111946630 @default.
• W2999597478 cites W2119049139 @default.
• W2999597478 cites W2146264128 @default.
• W2999597478 cites W2149091051 @default.
• W2999597478 cites W2150219016 @default.
• W2999597478 cites W2167245776 @default.
• W2999597478 cites W2176459589 @default.
• W2999597478 cites W2224883440 @default.
• W2999597478 cites W2292665223 @default.
• W2999597478 cites W2302367542 @default.
• W2999597478 cites W2336015782 @default.
• W2999597478 cites W2500767839 @default.
• W2999597478 cites W2531626219 @default.
• W2999597478 cites W2555612317 @default.
• W2999597478 cites W2609102185 @default.
• W2999597478 cites W2626446274 @default.
• W2999597478 cites W2726939337 @default.
• W2999597478 cites W2778376267 @default.
• W2999597478 cites W2811102551 @default.
• W2999597478 cites W2882027072 @default.
• W2999597478 cites W2965056983 @default.
• W2999597478 cites W4241721607 @default.
• W2999597478 doi "https://doi.org/10.3390/jcm9010259" @default.
• W2999597478 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7019437" @default.
• W2999597478 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31963648" @default.
• W2999597478 hasPublicationYear "2020" @default.
• W2999597478 type Work @default.
• W2999597478 sameAs 2999597478 @default.
• W2999597478 citedByCount "38" @default.
• W2999597478 countsByYear W29995974782020 @default.
• W2999597478 countsByYear W29995974782021 @default.
• W2999597478 countsByYear W29995974782022 @default.
• W2999597478 countsByYear W29995974782023 @default.
• W2999597478 crossrefType "journal-article" @default.
• W2999597478 hasAuthorship W2999597478A5007204226 @default.
• W2999597478 hasAuthorship W2999597478A5013273392 @default.
• W2999597478 hasAuthorship W2999597478A5030439670 @default.
• W2999597478 hasAuthorship W2999597478A5071307339 @default.
• W2999597478 hasAuthorship W2999597478A5087216936 @default.
• W2999597478 hasBestOaLocation W29995974781 @default.
• W2999597478 hasConcept C126322002 @default.
• W2999597478 hasConcept C134018914 @default.
• W2999597478 hasConcept C168563851 @default.
• W2999597478 hasConcept C2776954865 @default.
• W2999597478 hasConcept C2777180221 @default.
• W2999597478 hasConcept C2777538456 @default.
• W2999597478 hasConcept C2778384471 @default.
• W2999597478 hasConcept C2778772119 @default.
• W2999597478 hasConcept C2779134260 @default.
• W2999597478 hasConcept C2779306644 @default.
• W2999597478 hasConcept C2780323712 @default.
• W2999597478 hasConcept C555293320 @default.
• W2999597478 hasConcept C71924100 @default.
• W2999597478 hasConcept C90924648 @default.
• W2999597478 hasConceptScore W2999597478C126322002 @default.
• W2999597478 hasConceptScore W2999597478C134018914 @default.
• W2999597478 hasConceptScore W2999597478C168563851 @default.
• W2999597478 hasConceptScore W2999597478C2776954865 @default.
• W2999597478 hasConceptScore W2999597478C2777180221 @default.
• W2999597478 hasConceptScore W2999597478C2777538456 @default.
• W2999597478 hasConceptScore W2999597478C2778384471 @default.
• W2999597478 hasConceptScore W2999597478C2778772119 @default.
• W2999597478 hasConceptScore W2999597478C2779134260 @default.
• W2999597478 hasConceptScore W2999597478C2779306644 @default.
• W2999597478 hasConceptScore W2999597478C2780323712 @default.
• W2999597478 hasConceptScore W2999597478C555293320 @default.
• W2999597478 hasConceptScore W2999597478C71924100 @default.
• W2999597478 hasConceptScore W2999597478C90924648 @default.
• W2999597478 hasIssue "1" @default.
• W2999597478 hasLocation W29995974781 @default.
• W2999597478 hasLocation W29995974782 @default.
• W2999597478 hasLocation W29995974783 @default.
• W2999597478 hasLocation W29995974784 @default.
• W2999597478 hasLocation W29995974785 @default.
• W2999597478 hasOpenAccess W2999597478 @default.

• next